Under the guidance of drug delivery guru Dr. Robert Langer of MIT and Massachusetts General Hospital's Dr. William Crowley, Boston's Columbia Laboratories has acquired the license to an intravaginal ring designed to deliver several different drugs at a time.
A month after Genmab and Johnson & Johnson's Janssen released successful mid-stage data for its multiple myeloma antibody daratumumab, Halozyme has jumped on board, planning a Phase I trial with its subcutaneous delivery technology. Read more >>
Citing rampant use of the same needle to inject more than one person, the World Health Organization has--some might say finally--launched a new policy to make unsafe injections less prevalent. Part of this policy involves adopting up-to-date measures in syringe engineering, promoting the use of "smart" needles with precautions against unsafe use. Read more >>
POPULAR COMMENT THREADS
The developer of a novel drug delivery platform for nitric oxide just raised $50 million in a financing round led by Irish life science investment fund Malin.
Scientists at Japan's Kyushu University claim to have developed a technique for dispersing carbon nanotubes made of graphene while preserving their desirable properties like conductivity, durability and length.
MultiVir, a developer of viral vectors to deliver anticancer gene therapy, just filed for a $70 million IPO with the Securities and Exchange Commission as it seeks funding for clinical trials of its Phase I/II lead candidates for colorectal cancer and head and neck cancer, and to take the first FDA-approved gene therapy to the market.
Pennsylvania nanotech company Genisphere announced this week that in preclinical studies its 3DNA platform has successfully treated a cataract surgery complication called posterior capsular opacification.
A team of researchers is developing a new form of microbubble delivery, deploying ultrasound to implode the bubbles into several smaller nanobubbles that can cross biological barriers due to their size and release the payloads within the target area.
To transport a hunger-suppressing molecule to the gut as a treatment for obesity, researchers at Vanderbilt University have put bacteria to work. The bacteria become lodged in the digestive system and release the lipid for up to a year at a time, altering the gut microbiome to stave off weight-related problems like diabetes and heart disease.
From Our Sister Sites
Chris Garabedian, the bullish, controversial CEO of Sarepta Therapeutics, has resigned from his post, leaving the company just as it prepares to file its Duchenne muscular dystrophy treatment for FDA approval.
23andMe is making its first foray into retail, teaming up with U.K. health and beauty company Superdrug to sell its genetic tests in the country.